Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop
New York, Jan 12, 2026, 15:14 (EST) — Regular session Mesoblast Ltd’s shares on the U.S. market dropped roughly 11% Monday, sliding to $18.64 in afternoon trading after hitting $20.14 earlier. The Australian biotech’s stock has seen sharp swings since it started highlighting early commercial progress for its main cell therapy. The pullback is significant since Mesoblast has moved beyond being just a clinical-stage story, now driven by product sales and cash flow. Investors have been parsing every update on Ryoncil sales and financing as a gauge of the company’s actual runway. A director’s share purchase in Australia failed to
